Electrocore Stock Price, News & Analysis

electroCore, Inc. (Nasdaq: ECOR) announced the appointment of Peter Cuneo as Chairman of the Board, effective October 1, 2021. Cuneo, who joined the board in April 2020, succeeds Mike Atieh but will remain an independent director. With over 35 years of experience, Cuneo has led various successful companies including Marvel Entertainment and Remington Products. CEO Dan Goldberger expressed confidence in Cuneo's leadership to drive the company’s future, particularly in expanding its gammaCore therapy for treating migraine and cluster headaches.

electroCore, Inc. (Nasdaq: ECOR) announced the issuance of US Patent No. 11,097,102 by the U.S. Patent Office, expanding its portfolio of smartphone-integrated non-invasive therapy devices. This patent is part of the company's strategy to leverage mobile connectivity in delivering Vagus Nerve Stimulation (nVNS) therapy. The integration could enable new business models and revenue streams through Remote Patient Monitoring. The company aims to enhance its product offerings and patient care, potentially reaching millions globally.

electroCore, Inc. (Nasdaq: ECOR) announced FDA clearance for gammaCore nVNS's label expansion to treat Paroxysmal Hemicrania (PH) and Hemicrania Continua (HC) in adults, effective September 10, 2021. This non-invasive treatment shows promise for patients suffering from these rare types of headaches, with clinical audits indicating that 79% of patients experienced significant relief. gammaCore is also already indicated for cluster headaches. This clearance opens up new treatment avenues for debilitating headache conditions, offering patients a much-needed alternative.

electroCore, a commercial-stage bioelectronic medicine company (NASDAQ: ECOR), will present at the HC Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available online starting at 7:00 am EDT on September 13. Investors can register for the conference through provided links. A webcast replay will be accessible on the company’s website after the conference. electroCore focuses on non-invasive vagus nerve stimulation therapy aimed at treating conditions like migraines and cluster headaches.

electroCore (Nasdaq: ECOR) announced a new reseller agreement with Red One Medical Devices, enhancing the availability of its gammaCore therapy within the federal marketplace. This collaboration targets U.S. Department of Veterans Affairs and Department of Defense hospitals, aiming to provide support to military personnel suffering from severe headaches. The partnership is set to streamline procurement processes, facilitating quicker access to gammaCore’s non-invasive vagus nerve stimulation therapy, which is designed for migraine and cluster headache relief.

electroCore, Inc. (Nasdaq: ECOR) announced the publication of a study in the Journal of Affective Disorders Reports, highlighting the effects of non-invasive vagus nerve stimulation (nVNS) on PTSD symptoms. Conducted at Georgia Tech and Emory University, the randomized trial showed a significant 31% reduction in PTSD symptoms and improvement in hyperarousal through nVNS after three months (p<0.013). The study indicates nVNS can effectively block inflammation markers related to PTSD, showcasing potential in addressing unmet medical needs for the estimated 8 million Americans suffering from PTSD annually.

electroCore reports strong second quarter 2021 results with net sales of $1.3 million, up 69% year-over-year and 5% sequentially. Revenue from the VA and DoD increased 15% sequentially to $779,000. The company’s cash balance at June 30, 2021, stood at approximately $23.7 million, bolstered by a recent public offering yielding $18.8 million net proceeds. Despite a GAAP net loss of $2.9 million, this marks a 39% improvement from a year ago. The company anticipates third quarter revenue of at least $1.5 million.

On August 4, 2021, electroCore announced the publication of an article in PharmacoEconomics that highlights the cost-effectiveness of gammaCore for treating cluster headaches. It shows that gammaCore therapy can save £450 per patient in the first year compared to standard treatments, while also reducing headache frequency and severity. The UK National Institute for Health and Care Excellence (NICE) guidance supports the adoption of gammaCore in the NHS, aiming to enhance its market presence. Iain Strickland noted the significance of NICE’s endorsement for growth in the UK market.

On August 2, 2021, electroCore announced its participation in the Canaccord Genuity Growth Conference, set for August 10-12, 2021. The company's management will present on August 12 at 8:30 am EDT. This conference offers a platform for virtual one-on-one meetings with investors. Following the event, a recording of the presentation will be accessible on the investor section of the company's website. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies for neurological conditions, including migraine and cluster headaches.